Evidence map›Paper›PMID 36595075›Full record

ArticleSurgery today2023

The prognostic impact of the lymphocyte-to-C-reactive protein ratio in patients with unresectable or recurrent advanced gastric cancer treated with first- and second-line treatment.

Tomoyuki Matsunaga, Hiroaki Saito, Yoji Fukumoto, Hirohiko Kuroda, Kenjiro Taniguchi, Sadamu Takahashi, Tomohiro Osaki, Akemi Iwamoto, Kenji Fukuda, Shota Shimizu and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Tomoyuki MatsunagaDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, 683-8504, Japan. matut0m0@tottori-u.ac.jp.
Hiroaki SaitoDepartment of Surgery, Japanese Red Cross Tottori Hospital, Tottori, 680-8517, Japan.
Yoji FukumotoDivision of Gastroenterology, Matsue City Hospital, Matsue, 690-8509, Japan.
Hirohiko KurodaDepartment of Surgery, Japanese Red Cross Masuda Hospital, Masuda, 698-8501, Japan.
Kenjiro TaniguchiDepartment of Surgery, Yonago Medical Center of National Hospital Organization, Yonago, 683-0006, Japan.
Sadamu TakahashiNational Hospital Organization, Hamada Medical Center, Hamada, 697-8511, Japan.
Tomohiro OsakiDepartment of Surgery, Tottori Prefectural Central Hospital, Tottori, 680-0901, Japan.
Akemi IwamotoDivisions of Digestive Surgery, Tottori Prefectural Kousei Hospital, Kurayoshi, 682-0804, Japan.
Kenji FukudaDepartment of Surgery, Sanin Rosai Hospital, Yonago, 683-8605, Japan.
Shota ShimizuDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, 683-8504, Japan.
Yuji ShishidoDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, 683-8504, Japan.
Kozo MiyataniDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, 683-8504, Japan.
Yoshiyuki FujiwaraDivision of Gastrointestinal and Pediatric Surgery, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University, 36-1 Nishi-Cho, Yonago, 683-8504, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe goal of this study was to determine which markers are the most useful as first- and second-line pre-treatment markers in patients with unresectable or recurrent gastric cancer (URGC).

methodsThis study included 101 URGC patients who were treated with first- and second-line chemotherapy. Several prognostic scores based on nutrition and inflammation were analyzed using a receiver operating characteristic (ROC) analysis to determine the most useful prognostic marker.

resultsThe lymphocyte-to-C-reactive protein ratio (LCR) had the highest area under the curve for both first- and second-line chemotherapy, according to an ROC analysis. An ROC analysis was used to determine the optimal LCR cut-off for the median survival time before first- and second-line chemotherapy, and patients were divided into high- and low-LCR groups. Patients with a high LCR had a significantly longer survival than those with a low LCR before first- and second-line chemotherapy (p = 0.004, p < 0.001, respectively). A low LCR before both first- and second-line chemotherapy was an independent poor prognostic factor in a multivariate analysis.

conclusionsURGC patients with a low LCR before both first- and second-line chemotherapy had a significantly worse prognosis than those with a high LCR in this study. Nutritional intervention during chemotherapy induction may lead to a better prognosis.

Indexed as

Stomach NeoplasmsC-Reactive ProteinHumansLymphocytesNeoplasm Recurrence, LocalPrognosisRetrospective StudiesC-Reactive ProteinGastric cancerLCR

Identifiers

PMID36595075

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.